Some in the Ozarks struggling to pay for insulin despite lower drug prices
“Insulin used to cost around $500 for one box, and now it’s down to somewhere around $150, $200, so they’ve really dropped ...
Gov. Ned Lamont unveils proposals to tackle prescription drug costs
There’s an ongoing push to improve health care affordability and reduce out-of-pocket costs, especially for prescription ...
Medtronic: Undervalued But Underperforming - Why Innovation Isn't Enough To Lift The Stock
Medtronic's stock lags peers due to growth challenges in the diabetes and hypertension markets. See why we recommend a sell ...
Embecta raises FY2025 adjusted EBITDA margin guidance to 37% amid cost-cutting and debt reduction focus
Adjusted EBITDA margin increased to 37.2% from 25.2% in Q4 2024, driven by cost reductions and operational improvements. Management's tone shifted positively, highlighting stronger-than-expected ...
Lilly's Growth in Diabetes and Obesity, and Strong Oncology and Immunology Drugs Create a Wide Moat
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
People with diabetes could be due up to £737 each month through PIP or ADP
People in Scotland may be eligible for Adult Disability Payment to help with daily living or mobility costs as a result of diabetes.
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.